Genomic testing to guide treatment decisions for women with ovarian cancer is in its early days. However, as more platforms become commercially available, physicians will need to understand the similarities and differences between tests.
Maintenance therapy with olaparib following chemotherapy is the new standard of care for women with BRCA–mutated ovarian cancer.
The FDA has issued a letter to healthcare providers that they should monitor patients with a type of peripheral arterial disease who have been treated with vascular balloons that were coated with paclitaxel or stents that release paclitaxel in the femoropopliteal artery in the leg.
Neil Horowitz, MD, discusses surgical options for patients with newly diagnosed ovarian cancer.
Suzanne George, MD, highlights the available therapies for patients with uterine sarcomas and what novel options are on the horizon.
Nearly 1 IN 5 women who undergoes ovarian cancer surgery is readmitted for complications, but a web-based app may improve patient monitoring so complications and adverse events can be addressed quickly by the patient’s care team.
Joyce F. Liu, MD, MPH, highlights the recent changes in the newly diagnosed ovarian cancer space and what the oncology field could see by the end of 2019.
A targeted liquid biopsy may have the potential to serve as an early diagnostic tool for endometrial cancer.
The presence of specific subtypes of HPV, namely HPV-16 and -18, were found to be associated with a higher risk of developing high-grade cervical intraepithelial neoplasia in women under the age of 30.
The impact of subsequent lines of treatment on trial outcomes can be substantial, seriously challenging the relevance of OS as an objectively meaningful study endpoint.